source
- The patent cliff is looming and CDMOs need to be prepared, Fujifilm CEO saysAs drugmakers prepare for the looming biopharma patent cliff, 2026 has so far been a year for dealmaking. Now, contract manufacturers need to broaden their services to keep up, Fujifilm Biotechnolo…
- Argenx to acquire Forte in $2.2B deal for ‘differentiated’ immune drugThe deal gives Argenx a drug prospect aimed at the protein target CD122, an approach that’s recently gained traction among multiple developers.